Clinical Effect of Anlotinib Capsules Combined with Immune First-line Maintenance Treatment for Extensive Stage-small Cell Lung Carcinoma
Objective:To investigate the application effect of Anlotinib Capsules combined with immune first-line maintenance treatment for extensive stage-small cell lung carcinoma.Method:A total of 78 patients with extensive stage-small cell lung carcinoma treated in Jiangxi Chest Hospital from December 2021 to December 2022 were selected as the study objects,and were divided into study group and control group according to random number table method,with 39 cases in each group.The control group was treated with immune first-line maintenance therapy,and the study group was treated with Anlotinib Capsules on the basis of the control group.Objective response rate(ORR),disease control rate(DCR),serum vascular endothelial growth factor(VEGF),basic fibroblast growth factor(bFGF)before and after treatment and safety were compared between the two groups.Result:The ORR and DCR of the study group were better than those of the control group(P<0.05).After treatment,serum VEGF and bFGF levels in the study group were significantly lower than those in the control group(P<0.01).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion:Anlotinib Capsules combined with immune first-line maintenance treatment for extensive stage-small cell lung carcinoma can improve the overall efficacy,effectively inhibit tumor angiogenesis,induce tumor cell apoptosis,and have good safety.
万方数据
维普
